Clinical Trial

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, immunogenicity and preliminary efficacy of engineered dendritic cells（eDCs）loaded with mKRAS antigen (CAT-101) alone or in combination with Tislelizumab (anti-PD-1 monoclonal antibody) among participants with KRAS-G12C/D/R/V mutated advanced pancreatic cancer and other solid tumors.
Trial Details
NCT Number NCT07396090
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Advanced Solid Tumor
Enrollment 13 participants
Start Date 2026-01-20
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09